KIT tyrosine kinases, critical in the oncogenesis of imatinib mesylate-sensitive gastrointestinal stromal tumors (GISTs), suggest the possibility of using imatinib in MCC therapies as well. This evidence concerns the gene KIT and Merkel cell skin cancer.